Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$572M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$495M |
| 3 |
iShares MBS ETF
MBB
|
+$405M |
| 4 |
Procter & Gamble
PG
|
+$365M |
| 5 |
Microsoft
MSFT
|
+$327M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$605M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$544M |
| 3 |
Sempra
SRE
|
+$474M |
| 4 |
CELG
Celgene Corp
CELG
|
+$411M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$380M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.85% |
| 2 | Healthcare | 5.77% |
| 3 | Financials | 5.26% |
| 4 | Consumer Discretionary | 4.71% |
| 5 | Communication Services | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Neurocrine Biosciences
NBIX
$16.7B
| $7.63M | ﹤0.01% |
71,004
+18,501
| +35% | +$1.94M |
|
1602
EPAM Systems
EPAM
$5.08B
| $7.63M | ﹤0.01% |
35,977
-5,911
| -14% | -$1.16M |
|
|
RARX
1603
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $7.62M | ﹤0.01% |
162,443
+143,217
| +745% | +$6.33M |
|
1604
CubeSmart
CUBE
$9.2B
| $7.6M | ﹤0.01% |
241,558
-132,341
| -35% | -$4.25M |
|
1605
CALL
Kimberly-Clark
KMB
$36.1B
| $7.59M | ﹤0.01% |
55,200
-50,400
| -48% | -$6.82M |
|
1606
Reinsurance Group of America
RGA
$15.9B
| $7.59M | ﹤0.01% |
46,567
-76,069
| -62% | -$12.3M |
|
1607
DexCom
DXCM
$33.1B
| $7.59M | ﹤0.01% |
138,740
-16,244
| -10% | -$770K |
|
1608
CALL
Targa Resources
TRGP
$56.9B
| $7.57M | ﹤0.01% |
185,500
-3,200
| -2% | -$124K |
|
|
ENLC
1609
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $7.56M | ﹤0.01% |
1,232,766
+160,981
| +15% | +$977K |
|
1610
Emcor
EME
$36.1B
| $7.56M | ﹤0.01% |
87,544
+15,076
| +21% | +$1.33M |
|
|
CONE
1611
DELISTED
CyrusOne Inc Common Stock
CONE
| $7.55M | ﹤0.01% |
115,479
-17,087
| -13% | -$1.17M |
|
1612
PUT
Bausch Health
BHC
$2.39B
| $7.55M | ﹤0.01% |
252,400
+47,200
| +23% | +$1.23M |
|
|
X
1613
CALL
DELISTED
US Steel
X
| $7.54M | ﹤0.01% |
660,600
-227,800
| -26% | -$2.83M |
|
1614
NovaGold Resources
NG
$3.36B
| $7.54M | ﹤0.01% |
841,082
+592,056
| +238% | +$4.1M |
|
1615
Generac Holdings
GNRC
$12.4B
| $7.52M | ﹤0.01% |
74,746
+15,218
| +26% | +$1.42M |
|
1616
CALL
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.59B
| $7.51M | ﹤0.01% |
253,300
-31,900
| -11% | -$899K |
|
1617
Vistra
VST
$48.2B
| $7.51M | ﹤0.01% |
326,595
-240,130
| -42% | -$6.2M |
|
|
MRTX
1618
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.5M | ﹤0.01% |
58,171
+36,799
| +172% | +$3.55M |
|
1619
PUT
AstraZeneca
AZN
$251B
| $7.49M | ﹤0.01% |
75,100
+3,650
| +5% | +$344K |
|
|
SAFM
1620
DELISTED
Sanderson Farms Inc
SAFM
| $7.49M | ﹤0.01% |
42,492
+9,429
| +29% | +$1.49M |
|
|
XEC
1621
DELISTED
CIMAREX ENERGY CO
XEC
| $7.49M | ﹤0.01% |
142,594
-121,366
| -46% | -$5.64M |
|
1622
Asbury Automotive
ABG
$3.8B
| $7.48M | ﹤0.01% |
66,923
+4,231
| +7% | +$455K |
|
1623
Brink's
BCO
$4.57B
| $7.47M | ﹤0.01% |
82,384
+47,208
| +134% | +$4.17M |
|
1624
Inspire Medical Systems
INSP
$1.74B
| $7.47M | ﹤0.01% |
100,659
+25,421
| +34% | +$1.63M |
|
1625
iShares US Telecommunications ETF
IYZ
$1.23B
| $7.47M | ﹤0.01% |
+250,000
| New | +$7.36M |
|
Similar funds
Barclays's Q4 2019 Portfolio in Review
As of Q4 2019, Barclays held 7,254 positions worth $180B, up 13% from $160B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Barclays deployed $6.1B of net new capital in Q4 2019, opening 260 new positions and adding to 3,541 existing holdings. Its largest new stake was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
By sector, the portfolio is most concentrated in Technology at 8.9% of assets, up from 7.7% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $605M trimmed.
- Barclays's largest Q4 2019 buy was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
- Barclays added most to Apple in Q4 2019, an estimated $572M increase.
- Barclays's biggest Q4 2019 reduction was Invesco QQQ Trust, cutting an estimated $605M.
- Barclays fully exited Celgene Corp in Q4 2019, selling an estimated $411M.
- Barclays's ten largest holdings make up 26% of its $180B portfolio in Q4 2019.
- Barclays opened 260 new positions and closed 700 in Q4 2019.
- Barclays's portfolio value rose 13% quarter-over-quarter to $180B.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.